Politics

Ethics Watchdog Urges Investigation Into Top Health Official, Alleging Conflict of Interest Over Hormone Therapy Policy

Read full article at source ↗

Based on a feed excerpt; full article content has not been acquired. Source evidence retrieved 13/11/2026, 23:24:25 UTC.

Briefings

The Campaign Legal Center is urging an investigation into Alicia Jackson, director of the Advanced Research Projects Agency for Health, alleging a conflict of interest over hormone therapy policy. A ProPublica investigation previously revealed Jackson endorsed a policy shift that benefited a company she owns stock in, and questioned her disclosure of $400 million in assets held by her husband's firm. Jackson was placed on administrative leave after the Department of Health and Human Services announced the removal of black box warnings from hormone replacement products. Federal ethics laws prohibit government employees from participating personally in matters that could influence their financial interests, though Jackson and HHS have not confirmed whether she obtained a waiver. The Campaign Legal Center also noted that Jackson's financial disclosures remain uncertified and that her agency has issued over $1.5 billion in contracts and grants.

Key points

• Alicia Jackson, director of the Advanced Research Projects Agency for Health, publicly endorsed a federal policy change on hormone replacement therapies while owning stock in a company providing menopause treatments.
• The Campaign Legal Center questioned whether Jackson properly disclosed up to $400 million in assets held by her husband's investment firm, noting her financial disclosures remain uncertified.

Context

This briefing covers a recent conflict of interest allegation against Alicia Jackson, a top HHS official. A ProPublica investigation previously found Jackson spoke at an HHS press conference and was quoted in a news release announcing the removal of black box warnings from hormone replacement products. The Campaign Legal Center is now calling for an investigation into whether she violated ethics laws by failing to recuse herself from matters that could influence her personal finances.

Limitations

The evidence is limited to a letter from the Campaign Legal Center and a summary of a ProPublica investigation. The specific role Jackson played in the decision to drop the black box warning is unclear. The HHS inspector general has not confirmed or denied whether it is investigating Jackson, and neither Jackson nor HHS has publicly explained why she was placed on administrative leave.

Generated by Bittrees-hosted qwen35-2b sha256:aaf42c8b7c3c on 13/11/2026, 23:35:25 UTC. Based on publisher-provided feed evidence; may not cover the full original article. Check the source for details.

View archived briefing on IPFS
bafybeidsicihq5lw6tiy42m76wdse3mes4km6scc32nl7pbjh655zuf53a